ICYMI: Last week’s leading headlines
Click Here to Manage Email Alerts
Keep up to date with the big news in ophthalmology.
Here are some important stories you might have missed on Healio.com/OSN from the past week:
Needling revision beneficial after Xen implantation
Patients with elevated IOP due to either a fibrotic or shallow bleb or increased vascularity after Xen gel stent implantation experienced a mean 35.9% IOP reduction from preoperative levels after undergoing a needling revision, according to a study. Read more.
Vision 2020 reaches landmark year
The 2020 landmark year of the Global Initiative for the Elimination of Avoidable Blindness opens with a positive balance. As stated in the latest World Report on Vision, “a strong platform of success on which to build future actions” is now in place thanks to the concerted efforts of the WHO, the International Agency for the Prevention of Blindness, and many nongovernmental and governmental partners. Read more.
Oxurion’s DME therapy shows positive phase 1 results
The open-label, multicenter, single dose escalation study evaluated the safety of a single intravitreal injection of three increasing doses (0.4 mg, 1 mg and 2.5 mg) of THR-687, a novel pan-RGD integrin antagonist. Read more.
CPT codes available for Notal Vision’s home OCT system
The CPT codes, 0604T, 0605T and 0606T, allow for billing for the device, set-up and patient education, as well as for the company’s diagnostic clinic, which provides technical support, data analyses and reports to physicians. Read more.
Allysta doses first patient in phase 1/2a dry eye trial
A novel peptide agonist that binds to and activates adiponectin receptors, ALY688 acts to reduce inflammation and promote healing of the cells lining the ocular surface. Read more.